Skip to content
Screener

Kura Oncology KURA Q1 2026 earnings

Reported May 12, 2026 · After market close

Revenue$18.3MMiss by $7.7M
EPS-$0.83Beat by $0.05
Revenue estimate$26.0M
EPS estimate-$0.88

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$23.8M
EPS estimate-$0.84

Financials

Q1 2026

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M—
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$718.12M+34.7%
Enterprise value$703.31M+40.4%
P/S10×+0.2×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Segments

By product

See full
License And Collaboration Revenue$12.5M-11.4%
Development Services For Monotherapy$7.2M—
Development Services In Combination With Other Therapies$5.3M—

FAQ

When did Kura Oncology report Q1 2026 earnings?
Kura Oncology (KURA) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Kura Oncology's Q1 2026 revenue and EPS?
Kura Oncology reported revenue of $18.3M and eps of $-0.83 for Q1 2026.
Did Kura Oncology beat estimates in Q1 2026?
Revenue missed the consensus estimate of $26.0M by $7.7M. EPS beat the consensus estimate of $-0.88 by $0.05.
How did Kura Oncology's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 29.5% from $14.1M a year earlier and eps declined 25.8% from $-0.66.
Where can I find Kura Oncology's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219422) and the 10-Q periodic report (0001193125-26-219481) directly on SEC EDGAR. The filing index links above go to sec.gov.